Philadelphia, Pennsylvania–(Newsfile Corp. – November 30, 2022) – As announced by the DOJ, the settlement resolves a lawsuit filed and litigated by a former Biogen against Biogen under the whistleblower provisions of the federal False Claims Act, in which it was alleged that Biogen paid kickbacks to physicians to induce them to prescribe the company’s multiple sclerosis drugs. According to the relator’s complaint, from Jan. 1, 2009, through March 18, 2014, Biogen offered and paid remuneration, including in the form of speaker honoraria, speaker training fees, consulting fees and meals, to health care professionals who spoke at or attended Biogen’s speaker programs, speaker training meetings or consultant programs to induce them to prescribe the drugs Avonex, Tysabri and Tecfidera, in violation of the Anti-Kickback Statute.

If you are a current long-term Biogen shareholder, you may be able seek corporate reforms, the return of funds expended defending litigation back to company coffers, and a court approved incentive award if appropriate.

If you would like to learn more about this matter at no cost to you, visit https://grabarlaw.com/the-latest/biogen-shareholder-investigation/, contact us at [email protected], or call 267-507-6085.

Attorney Advertising Disclaimer

These materials have been prepared by the Grabar Law Office for informational purposes only and does not constitute legal advice. This information is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Prior results referred to in these materials do not guarantee or suggest a similar result in other matters.

Contact:

Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: [email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/146377